#68 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians need this evidence on cannabis efficacy for psychiatric conditions to counsel patients accurately about potential benefits and risks, since many patients self-treat depression and anxiety with cannabis without medical guidance. The research findings help establish whether cannabis represents a viable therapeutic option or whether patients should be directed toward established treatments like antidepressants or psychotherapy. Understanding the current evidence allows clinicians to have informed conversations with patients about alternative treatments and make evidence-based recommendations within their scope of practice.
A recent systematic review examining cannabis use for depression, anxiety, and PTSD found limited high-quality evidence supporting its efficacy for these conditions, with most studies being small, short-term, or observational in nature. While some patients report subjective symptom improvement, particularly for anxiety in the short term, robust randomized controlled trials demonstrating sustained clinical benefit are lacking, and cannabinoid dosing, formulation, and optimal patient selection remain poorly defined. Current evidence suggests that cannabis may provide temporary relief for some patients but should not replace evidence-based treatments such as psychotherapy or FDA-approved medications, which have substantially more rigorous safety and efficacy data. Additionally, regular cannabis use carries documented risks including dependence, cognitive impairment, and potential worsening of psychiatric symptoms in vulnerable populations, highlighting the need for careful patient screening and monitoring. Clinicians should counsel patients that while cannabis is legal in many jurisdictions, the psychiatric benefit-risk profile remains uncertain and that established treatments remain the standard of care for mood and anxiety disorders. When counseling patients interested in cannabis for mental health, physicians should emphasize the importance of continuing evidence-based therapies while setting realistic expectations about symptom control and monitoring for adverse effects.
“The evidence for cannabis in mood and anxiety disorders remains genuinely mixed, which is exactly what I tell patients: we have compelling anecdotal reports and some mechanistic rationale, but we lack the rigorous clinical trials that would let me prescribe it with the same confidence I’d use for an SSRI, and that absence of evidence matters in clinical decision-making.”
🧠 While many patients self-report symptom relief from cannabis use for depression and anxiety, the evidence base remains limited and mixed, with most studies being observational rather than randomized controlled trials. The neurobiological plausibility is intriguing—cannabinoids interact with serotonergic and GABAergic systems implicated in mood disorders—yet we lack clarity on optimal cannabinoid ratios, dosing, duration of use, and long-term safety profiles, particularly regarding cognitive effects and dependence risk. Important confounders include concurrent psychiatric medications, comorbid substance use, underlying diagnosis severity, and the placebo effect, which can be substantial in symptom-driven conditions like anxiety. Clinicians should remain cautious about endorsing cannabis as first-line therapy given the availability of evidence-based alternatives like psychotherapy and FDA-approved medications, while acknowledging that some patients may benefit from adjunctive use in carefully monitored
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
